Spanish pharma company Reig Jofre is investing a 30 million euros ($37 million) on expanding its injectable products plant in Barcelona.
The aim is to increase aseptic production capacities and production efficiencies, and to adapt the plant to new technologies to address more complex developments and meet the requirements of the most demanding markets.
There has been an increase in demand for existing injectable products already marketed by Reig Jofre, and brought about by the arrival of new, complex molecules whose instability requires freeze-drying in production.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze